EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, and MD Anderson Cancer Center announced a three-year strategic collaboration, with the aim of more quickly advancing the development of investigational cancer therapies in four cancers--breast, colorectal, glioblastoma and leukemia.
Vescor LLC, a new company focused on discovery and development of autophagy targeted therapeutics for cancer treatment, was formed by MD Anderson Cancer Center, Deerfield Management and two autophagy experts, Eileen White, deputy director and associate director for Basic Science, Rutgers Cancer Institute of New Jersey, and Alec Kimmelman, chairman, Department of Radiation Oncology at NYU Langone Medical Center and a member of the Perlmutter Cancer Center at NYU Langone.
Exact Sciences Corp. announced that the Blue Cross Blue Shield Association's Center for Clinical Effectiveness "Evidence Street" recently released a positive review of Cologuard to its members.
Mylan N.V. and Biocon Ltd. said FDA has accepted Mylan's biologics license application for MYL-1401O, a proposed biosimilar trastuzumab, for filing through the 351(k) pathway.
FDA released the final guidance for industry "Nonproprietary Naming of Biological Products."
Shimon SakaguchiFred RamsdellAlexander RudenskyThree immunology researchers shared the 2017 Crafoord Prize in Polyarthritis "for their discoveries relating to regulatory T cells, which counteract harmful immune reactions in arthritis and other autoimmune diseases."
Gustavo Leone was named director of the Medical University of South Carolina Hollings Cancer Center. His appointment begins March 1.
Levine Cancer Institute was named a “Planetree Designated Patient-Centered Organization,” making it the only cancer network worldwide to earn Planetree designation, the highest achievement in patient-centered care.
Martin Edelman joined Fox Chase Cancer Center as chair of the Department of Hematology/Oncology.
Diane Simeone will join the NYU Langone Medical Center's Perlmutter Cancer Center March 1 to serve as associate director for translational research and to lead its newly established pancreatic cancer center. Simeone is the director of the gastrointestinal oncology program at University of Michigan Comprehensive Cancer Center.
